GlassScriptPhysician profile
Vitaly Raykhman
NPI 1386656361
$2,145.74
in general payments reported to CMS, 2019-2025
26 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $120 · 2021: $426 · 2022: $527 · 2023: $276 · 2024: $183 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $341.84 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $296.66 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $216.65 | 2019-2020 | |
| Urovant Sciences INC | $208.04 | 2021-2022 | |
| Antares Pharma, INC. | $129.66 | 2021-2022 | |
| Teleflex LLC | $107.13 | 2021-2025 | Urolift |
| Abbvie INC. | $97.46 | 2021-2025 | |
| Myovant Sciences INC. | $83.27 | 2021-2022 | |
| Pfizer INC. | $81.73 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $76.48 | 2021-2022 | |
| Janssen Biotech, INC. | $70.54 | 2019-2023 | Erleada |
| Verity Pharmaceuticals INC. | $62.79 | 2021-2023 | Trelstar |
| Amag Pharmaceuticals, INC. | $46.01 | 2019 | |
| Endo Pharmaceuticals INC. | $40.12 | 2019-2024 | Xiaflex |
| Axonics, INC. | $30.91 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.87 | 2022 | |
| Hollister Incorporated | $26.21 | 2023 | Vapro Plus Pocket, Onli, Vapro |
| Neotract INC. | $26.10 | 2020 | |
| Dendreon Pharmaceuticals LLC | $25.40 | 2020 | |
| Progenics Pharmaceuticals, INC. | $24.94 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $24.35 | 2024 | Opdivo |
| Tolmar, INC. | $22.10 | 2025 | Eligard |
| Therapeuticsmd, INC. | $21.45 | 2019 | |
| Clarus Therapeutics INC. | $19.65 | 2021 | |
| Olympus America INC. | $19.63 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $18.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitaly Raykhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.